Regulated Supply and Harm Reduction Outcomes: Why Access Conditions Matter
Last Updated: February 2026 | Reading Time: 5 minutes
The research literature on cannabis harm reduction consistently finds that access conditions shape outcomes. It is not simply whether a person uses cannabis, but how they access it — at what cost, with what consistency, within what clinical or peer relationship — that appears to determine whether cannabis functions as a harm reduction tool or produces neutral or adverse effects. This article reviews four Canadian studies that make this case directly and draws out the structural implications.
The Authorized Patient Study: Cost and Consistency at Scale
Lucas, Baron & Jikomes (2019), examining 2,032 authorized patients in Canada’s federal medical cannabis program (Harm Reduction Journal, 16(1): 9), provide the baseline picture of what regulated access produces. Among this population, people who had navigated the authorization process and had access to a licensed, quality-controlled supply, 44.5% reported substituting cannabis for alcohol and 69.1% reported substituting for prescription medications.
These rates are from a population with stable, legal, regulated access: consistent supply, documented THC and CBD concentrations, a medical record of use, and in some cases federal coverage. This is the access condition that produces majority-rate substitution in a large Canadian cohort.
The distinction between medicinal and recreational cannabis use is not primarily pharmacological. It is structural: authorization brings supply consistency, documented concentrations, clinical oversight, and a prescribing relationship that shapes how and how much is used.
The Veteran Population: Use Characteristics and Perceived Benefit
Sheehy, Storey, Rash, Tippin, Parihar & Harris (2025), a cross-sectional analysis of 513 Canadian veterans with chronic pain and a history of trauma (Journal of Veterans Studies, 11(1): 30–46), examined whether differences in cannabis use characteristics were associated with differences in PTSD-related outcomes. The study found that cannabis use characteristics including medicinal versus recreational use, route of administration, THC to CBD ratio, and grams per day were not significantly correlated with PTSD severity, psychological distress, or insomnia in adjusted analysis.
Notably, the descriptive findings tell a different story: the majority of cannabis users in the sample reported that cannabis benefited their mental health. The authors note that veterans with more severe PTSD may be more likely to seek out a cannabis prescription, which complicates interpretation of the prescription group’s higher measured PTSD severity. The study highlights the need for longitudinal research to clarify which use characteristics are associated with better or worse outcomes over time, and whether perceived short-term benefits translate to measured long-term effects. For program developers, it is a useful corrective to overconfident claims in either direction about cannabis and PTSD, while confirming that this population is actively using cannabis as a coping tool.
The BCCSU Cohort: Craving Management and Daily Use
Reddon, Lake, Socias, Hayashi, DeBeck, Walsh & Milloy (2023), a cross-sectional study drawing on participants from BCCSU cohorts (International Journal of Drug Policy), examined 205 people who use cannabis and opioids in Vancouver. Using cannabis specifically to manage cravings was significantly associated with self-assessed substance reduction in adjusted analysis (aOR=2.13, p=0.032), as was daily cannabis use (aOR=3.87, p=0.028).
The paper names High Hopes Foundation among the peer-led, free cannabis distribution programs accessible to participants in the DTES, and descriptively observes that participants reporting both intentional craving management and substance reduction were more likely to access free distribution programs. The adjusted regression did not confirm free program access as an independent statistically significant predictor, suggesting that mode of use, specifically intentional craving management at consistent daily frequency, is the operative variable. Free access may nonetheless enable that mode of use for populations who could not otherwise afford consistency.
The DTES Distribution Study: Barriers as the Mechanism
Valleriani, Haines-Saah, Capler, Bluthenthal & Socias (2020), a qualitative study of DTES cannabis distribution programs including High Hopes Foundation (International Journal of Drug Policy, 79: 102737), directly examines the access barriers that prevent regulated cannabis from functioning as a harm reduction tool for marginalized populations.
Cost was the primary barrier: licensed cannabis was unaffordable for people living on disability support or in poverty, particularly at quantities needed for consistent use. Documentation and registration requirements created administrative obstacles for those without stable housing, government ID, or a regular healthcare provider. Stigma in clinical settings deterred some participants from seeking medical authorization.
The Valleriani et al. study is explicit about the nature of the programs it examined: neither High Hopes nor the other program studied received formal support from any licensed cannabis company, government body, or health agency at the time. These programs were community responses to the failure of the regulated system to reach this population. The study documents their design features as the mechanism enabling access: no-cost distribution, at sites participants already used, staffed by peer workers from the same community.
The Policy Implication
Taken together, these studies make a specific structural argument: harm reduction outcomes associated with cannabis are access-dependent. High-barrier, high-cost access produces inconsistent use and inconsistent outcomes. Low-barrier, low-cost, regulated access, whether through federal medical authorization with coverage or through peer-led distribution at no cost, creates the conditions under which consistent, intentional use can produce measurable harm reduction effects.
For institutions and programs evaluating cannabis harm reduction models, the question is therefore not only whether cannabis substitution works — the Goulet-Stock et al. (2026) Ottawa findings answer that in the affirmative with a quantified effect size. The question is what access conditions produce those outcomes. The Lucas, Reddon, and Valleriani studies together point to regulated supply, minimal cost barriers, and consistent availability as the structural requirements.
This article summarizes published peer-reviewed research for informational purposes. It does not constitute medical advice or policy guidance.
References
- Lucas, Baron & Jikomes (2019). Harm Reduction Journal, 16(1): 9. DOI: 10.1186/s12954-019-0278-6
- Reddon, Lake, Socias, Hayashi, DeBeck, Walsh & Milloy (2023). International Journal of Drug Policy. PMC10817207
- Sheehy, Storey, Rash, Tippin, Parihar & Harris (2025). Journal of Veterans Studies, 11(1): 30–46. DOI: 10.21061/jvs.v11i1.582
- Valleriani, Haines-Saah, Capler, Bluthenthal & Socias (2020). International Journal of Drug Policy, 79: 102737. DOI: 10.1016/j.drugpo.2020.102737